Company intelligence / Profile preview

Nodexus

San Jose, California, United Statesnodexus.com ↗

Ownership: Private
Development stage: Commercial

Overview

The NX One system enables gentle, affordable single-cell sorting and dispensing using disposable microfluidic cartridges. It supports contamination-free workflows for applications including gene editing (e.g., CRISPR), antibody development, tumor heterogeneity studies, and iPSC line generation. The company has raised $30M Series A to advance manufacturing and commercialization. No clinical results as it does not develop therapeutics.

Therapeutic areas: Oncology
Modalities: Device (cell sorting and dispensing systems)Microfluidics platform (enabling workflows for gene editing, stem cell research, etc.)
Industry: Non-Drug Biotech

Partnerships

RA Capital (investor/VC partner)Section 32 (investor/VC partner)

Beyond the preview

Go deeper on Nodexus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nodexus.

Explore the full profile